Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction.
Heng, Benjamin, Gunasegaran, Bavani, Krishnamurthy, Shivani et al. · Cell reports. Medicine · 2025 · DOI
Quick Summary
This study examined blood samples from ME/CFS patients and healthy people to understand what goes wrong in the body. Researchers found that immune cells in ME/CFS patients are struggling to make energy (ATP), the fuel that powers our cells. The immune system also showed signs of being immature or worn out, and blood proteins related to clotting and blood vessel problems were elevated, suggesting blood vessel dysfunction may contribute to ME/CFS symptoms.
Why It Matters
This study provides concrete biological evidence that ME/CFS involves measurable abnormalities in energy production, immune function, and blood vessel health—supporting the view that ME/CFS is a real physiological disease, not psychological. These findings could eventually lead to diagnostic tests and targeted treatments addressing the underlying causes rather than just managing symptoms.
Observed Findings
Immune cells from ME/CFS patients show elevated AMP and ADP with reduced ATP/ADP ratios, indicating cellular energy deficit.
ME/CFS patients display skewed immune cell differentiation with reduced mature CD4+ and CD8+ T cells and fewer specialized dendritic and natural killer cells.
Plasma proteomic analysis reveals elevated levels of proteins associated with thrombus formation and vascular reactivity in ME/CFS patients.
Classification and regression tree modeling identified variables with strong predictive potential for distinguishing ME/CFS from controls.
Inferred Conclusions
ME/CFS involves concurrent system dysfunction across energy metabolism, immune regulation, and vascular biology rather than a single isolated defect.
Cellular energy stress in immune cells may contribute to immunological dysfunction observed in ME/CFS patients.
Elevated thrombotic and vascular reactivity markers suggest endothelial dysfunction contributes to ME/CFS pathophysiology.
Remaining Questions
Do energy metabolism defects in immune cells cause the immune dysfunction, or do they result from chronic immune activation in ME/CFS?
Which of these biomarkers are most directly related to symptom severity, and do they change with disease progression or treatment?
What This Study Does Not Prove
This study does not prove that energy metabolism problems, immune changes, or vascular dysfunction directly cause ME/CFS symptoms or whether these are primary or secondary consequences of the illness. It identifies associations in one point-in-time snapshot and cannot establish whether these biomarkers change over disease course or predict treatment response.